Pinnacle Medicines raised $89 million in a Series B financing to advance its oral peptide drug programs, increasing total funding to $134 million. The round was co-led by LAV and Foresite Capital and included participation from Quan Capital, Hankang Capital, RA Capital Management, Logos Capital, Orbimed, and others. The company is leveraging a pill-based format inspired by demonstrated success converting peptide drugs into oral molecules. With additional capital, Pinnacle is positioned to support preclinical and early clinical development across its platform pipeline. The funding also underscores continued investor willingness to back oral delivery strategies in a market where modality differentiation can matter as much as target selection.